Contact

 

Prof. Dr. Markus Büchler

Secretariat:
Gerda Drexler
Phone: +49 6221 566201
Fax: +49 6221 565450
E-mail: Gerda.Drexler@med.uni-heidelberg.de

Department of General-, Visceral- and Transplant Surgery

 

Our group/department has:

  • Implemented a tissue service and biobank for collection and immediate processing of blood, bone marrow, serum and tissue samples from CRC patients undergoing resection of the primary tumor or metastases. This biobank meanwhile comprises probes and prospective clinical datasets from more than 2000 patients, and is complemented with infrastructure for detection and enumeration of circulating tumor cells in colorectal cancer patients.

  • Inaugurated a Clinical Research Unit (KFO 227) funded by the DFG, which aims at delineating key mechanisms underlying metastatic progression of colorectal cancer. This consortium has already generated crucial insights into genetic, molecular and cellular properties enabling colorectal cancer metastasis, and was recently approved for a second funding period by the DFG.

  • Initiated and coordinated a large randomized prospective multicenter trial, which examines various treatment strategies for colorectal cancer patients with metastatic disease (SYNCHRONOUS Trial). This trial is conducted together with the Clinical Study Center of the German Surgical Society (SDGC) in Heidelberg, and funded by the DFG/BMBF.

  • Identified the clinical significance of occult micrometastases in regional lymph nodes in patients with node-negative colorectal cancer (Rahbari et al., J Clin Oncol 2012).

  • Demonstrated the prognostic significance of circulating tumor cells in patients with primary colorectal cancer (Rahbari et al., Gastroenterology 2010).

2010 – 2013

  • Rahbari NN, Bork U, Motschall E, Thorlund K, Büchler MW, Koch M, Weitz J. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30(1):60-70

  • Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M, Reissfelder C, Klupp F, Fritzmann J, Wunder C, Benner A, Kloor M, Huth C, Contin P, Ulrich A, Koch M, Weitz J. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17(24):7654-63

  • Rahbari NN, Ulrich AB, Bruckner T, Münter M, Nickles A, Contin P, Löffler T, Reissfelder C, Koch M, Büchler MW, Weitz J. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg 2011; 253(3):522-33

  • Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M, Weitz J. Meta-analysis shows that detection of circulating tumor cells indicates poor survival in patients with colorectal cancer. Gastroenterology 2010; 138(5):1714-26

  • Stange DE, Engel F, Longerich T, Koo BK, Koch M, Delhomme N, Aigner M, Toedt G, Schirmacher P, Lichter P, Weitz J, Radlwimmer B. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 2010; 59(9):1236-44.

  • 2008 - 2012 Emmy Noether Program, German Research Foundation (DFG), Germany (SCHN 947/2-1; 1,238,050.00 EUR)

  • 2010 - 2013 Clinical Research Group KFO 227, German Research Foundation (DFG), Germany (total volume KFO: 3,649,000.00 EUR; C-Project: 949,700.00 EUR)

  • 2012 - 2015 Common Project of Clinical Research Group KFO 227, German Research Foundation (DFG), Germany: second funding period